Pioneering Fat Grafting Through Automation and Innovation

Reliable Results Begin with Reliable Processing
Fat grafting outcomes are unpredictable and the root cause is clear: inconsistent fat processing. Existing systems produce variable graft quality, limiting viability and leading to insufficient, unreliable results.

Introducing VIVO I
VIVO I is a patent-pending, next-generation fat processing device designed to eliminate these limitations and outperform current market leaders. Its advanced, automated processing technology consistently delivers high-quality grafts that enable predictable surgical results and long-term patient satisfaction.

Proven Innovation. Strong Market Pull.
Early proof-of-concept studies show VIVO I improves graft quality by 30% compared to today's state-of-the-art systems. With a defined R&D and EU regulatory pathway, Vivo MedTech is now seeking investment to accelerate bringing the product to market. Market traction is already strong, with letters of intent for 500+ devices ahead of commercialization in a global fat processing systems market valued at $384M in 2025, projected to grow at ~12% CAGR through 2034.

Want To Learn More?

Nicolai Mamsen, CEO

Email: nm@vivomedtech.com
Telefon: +45 2883 4120

Setting the new standard for fat processing - and the future of predictable outcomes.